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ABSTRACT OF THESIS 
 
 
 
SYNTHESIS AND CHARACTERIZATON OF CURCUMIN POLYMER FOR APPLICATION IN 
RADIATION INDUCED LUNG DAMAGE 
 
Radiotherapy is used as a primary treatment for many cancers, including lung cancer. Although 
radiotherapy has proven to be an effective cancer treatment, its use is heavily limited due to the 
peripheral toxicity to healthy tissue. In this work, the antioxidant, curcumin, was tested as a 
radioprotectant to reduce radiation damage to healthy cells. Curcumin has been limited in use 
due to its poor bioavailability. In order to avoid problems associated with free curcumin 
delivery, curcumin poly(beta-amino ester) (CPBAE) was synthesized.  
The first study investigated the in vitro radioprotection effect of curcumin in HUVEC dosed with 
gamma radiation. Cells treated with curcumin showed significantly less ROS development 
compared to both untreated radiated and non-radiated cells. Cells treated with curcumin 
showed a decrease in viability for both radiated and non-radiated cells. Curcumin pretreatment 
exhibited no reduction in γ-H2AX foci formation in cells after radiation damage. These results 
indicate that curcumin does not radioprotect cells in an in vitro model. 
In a second study, curcumin was polymerized using a Michael addition reaction to create a 
hydrolytically degradable poly(beta-amino ester).  Curcumin multiacrylate and isobutylamine 
reacted to form curcumin poly(beta-amino ester) (CPBAE). This polymer’s chemical structure 
and properties were characterized and nanoparticles were made from the polymer. 
Nanoparticles synthesized were able to successfully release curcumin through degradation, but 
at a low efficiency and extended time scale. 
KEYWORDS: Linear Polymer Synthesis, Nanoparticles, Radiation, Antioxidant, Curcumin, Cell 
Culture 
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Chapter 1: Introduction 
 
Radiation therapy is the targeting and delivery of ionizing radiation at a specific dose to 
a cancer site. Ionizing radiation is radiation that has enough energy to remove electrons from 
atoms or molecules causing a change in charge and unpairing electrons. Ionizing radiation 
comes in many forms including X-rays, gamma rays and high energy ultraviolet rays. All of these 
sources create free radicals when interfacing with tissue. Most of these free radicals are created 
from water molecules as they are the greatest constituent of biological material [1]. DNA 
damage to cancer cells is the primary goal of radiation therapy and it is caused by these free 
radicals breaking DNA strands. If a cell has sufficient damage done to the DNA, mitotic cell death 
or apoptosis will occur. Cancer cells are much more sensitive to DNA damage caused by 
radiation due its destructive effects in dividing cells. Cancer cells divide at a much greater rate 
than most other healthy cells, making radiation disproportionately more damaging to cancer 
cells and an effective treatment [2].  
Radiation therapy is used to treat many different cancer types including skin cancer, 
larynx carcinoma, lymphoma, head and neck cancers, prostate cancers, breast cancer, lung 
cancer and others [3]. Of these, lung cancer is an especially common and aggressive form of 
cancer, accounting for 13.3% of new cancer cases while also accounting for 26.5% of cancer 
deaths [4]. Lung cancer is conventionally treated through a combination of chemotherapy and 
radiotherapy. Treatment could greatly benefit from higher radiation dosing schedules though as 
higher radiation dose has correlated to higher survival rate in patients with non-small cell lung 
cancer treated with 3D-CRT radiation [5]. Despite this, radiation dose to the lungs is limited due 
to radiation induced fibrosis. Higher mean dose of radiation to the lungs increases the volume of 
fibrosis developed in the lungs and leads to pneumonitis [6]. If this risk of pneumonitis could be 
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reduced though, higher, more effective radiation doses could be used in treating lung cancer.  
Considering these factors, protection of healthy endothelial cells during lung cancer treatment 
was investigated in this work.  
This development of pneumonitis first begins will the introduction of excess reactive 
oxidative species (ROS) created by ionizing radiation. ROS are a natural part of cellular 
respiration where there is a constant state of developing and scavenging free radicals. Oxidative 
stress is achieved when the ROS generation exceeds the antioxidant capacity of the system. This 
results in damage to the cells and elicits other downstream actions, such as inflammation. 
Inflammation is the body’s natural response to harmful stimuli such as pathogens, cellular 
damage or in this case oxidative stress induced by radiation. Inflammation involves recruitment 
of leukocytes to the area in the process of wound healing. Acute inflammation recruits 
leukocytes which work to remove harmful stimuli and progress to restoration of functional 
tissue [7]. The constant state of oxidative stress created by radiation in endothelial cells is not 
acute inflammation though, it is characterized as chronic inflammation. Chronic inflammation 
occurs when the negative stimuli cannot be resolved by the recruited leukocytes. As the initial 
neutrophils were not able to solve the problem, macrophages are recruited and begin 
progressive and severe fibrosis to isolate the injury [8]. This severe fibrosis leads to reduced lung 
capacity, difficulty breathing and in severe cases, mortality for the patient. 
When the natural systems at work in the cells are no longer able to handle the oxidative 
load, supplemental antioxidants are useful to prevent further damage. In order to address this, 
curcumin was proposed as a radioprotectant of healthy cells during radiation treatment. 
Curcumin is a natural phenol molecule with anti-oxidant, anti-inflammatory and anti-cancer 
properties [9]. Curcumin has been shown to be safe in clinical trials, as both free curcumin [10] 
and in liposomal form [11].  Curcumin has also been shown to interact favorably with NF-KB, a 
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cellular mechanism which regulates apoptosis in both cancer cells and endothelial cells. Cancer 
cells are at an elevated expression of NF-KB, curcumin is able to reduce this expression and 
sensitize them to radiation induced death. In the case of healthy endothelial cells, the 
downregulation of NF-KB would reduce cell apoptosis and reduce surrounding toxicity.  
Curcumin also exhibits limitations as drug including poor aqueous solubility which leads 
to reduced tissue uptake and bioavailability. This combined with curcumin molecules reducing 
to metabolites in vivo has made it difficult to simply use high dose curcumin as an effective 
clinical treatment [12]. In theory, low bioavailability can be addressed through developing a 
nanoparticle delivery system. Poly(beta-amino esters) are a class of polymers that can readily be 
broken down through hydrolytic degradation. Curcumin PBAE (CPBAE) has been developed and 
is more stable than free curcumin, being able to achieve a sustained release profile over hours 
rather than minutes [13, 14]. Linear CPBAE can be formed into a nanoparticle and targeted to 
the lungs. These particles would ideally be delivered intravenously. Intravenous delivery 
requires that the nanoparticles are able to circulate in the bloodstream and directly interact 
with vascular endothelial cells however. Both of these factors are size dependent. Nanoparticles 
are able to circulate for an extended amount of time in the bloodstream in the 50-500 nm size 
range [15] and internalize into the endothelium in the 80-500nm size range [16]. Based on these 
factors and studies of nanoparticle systems in the lungs, an ideal range of size for particles 
would be 50-400nm [17]. 
In this work, a model was first developed that induces radiation damage to human 
umbilical vein endothelial cells in vitro. Radiation was shown to increase ROS generation, reduce 
cell viability and increase γ-H2AX foci formation. Following studies showed curcumin was able to 
reduce ROS generated from radiation. Curcumin was also shown to further reduce the viability 
of radiated cells though and had no impact on reducing γ-H2AX foci formation. In a second 
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study, curcumin was polymerized using a Michael addition reaction to create a linear, 
hydrolytically degradable poly(beta-amino ester). The linear polymer was successfully formed 
into nanoparticles. It was found that the polymer released curcumin over a 15 day period.            
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Chapter 2: Background 
 
2.1  Radiation therapy and mechanism 
2.1.1 Ionizing radiation 
 Ionizing radiation is radiation that has enough energy to remove free electrons from 
atoms or molecules causing a change in charge and ionizing them. This includes particulate 
radiation such as α particles, β particles and cosmic rays and photon radiation including X-rays, γ 
rays and extreme ultra violet radiation [18]. Particulate radiation has the added aspect of kinetic 
energy that it can directly alter the structure of molecules and proteins while photon ionizing 
radiation acts solely through removing electrons from molecules.  
2.1.2 Ionizing radiation interaction with cells 
DNA damage to cancer cells is the primary goal of radiation therapy and it is caused by 
free radicals breaking DNA strands. Most of these free radicals are created from water 
molecules as they are the greatest constituent of biological material [1]. When a cell has 
sufficient damage done to the DNA from free radical damage, mitotic cell death or apoptosis will 
occur. Cancer cells are much more sensitive to DNA damage caused by radiation due its 
destructive effects in dividing cells. Cancer cells divide at a much greater rate than most other 
healthy cells, making radiation disproportionately more damaging to cancer cells and an 
effective treatment [2].  
2.1.3 Ionizing radiation sources 
 The two types of ionizing radiation conventionally used in radiotherapy are gamma rays 
and X-rays. Although gamma radiation and x-rays are separately defined on the electromagnetic 
spectrum, these two types of radiation are conventionally differentiated by how they produced 
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rather than the characteristics of the emitted radiation. Gamma rays are produced by 
radioactive decay of materials, where most commonly used materials for medical use are 
Cobalt-60 and Cesium-137. X-rays on the other hand are produced by electrons being ejected 
from the shell of an atom. X-rays and gamma rays are both measured for dosing in gray units 
and intensity of the source is measured in electron volts (eV). A gray unit is defined as one joule 
of ionizing radiation absorbed in one kilogram of material. The intensity of the source is either 
proportional to the wavelength on the electromagnetic spectrum if produced as an X-ray or 
characteristic of the emission of a specific radioactive material [18].  Cobalt-60 has a decay 
energy of 2.844 MeV while Cesium-137 has a decay energy of 1.176 MeV [19].  As defined by the 
electromagnetic spectrum, gamma rays occupy shortest wavelength of energy and highest 
energy at wavelengths less than 10-11m. X-rays occupy the range from 10-12m to 10-9m. There is 
overlap in this range, and many clinical X-rays use intensities similar to gamma radiation sources 
[20-23]. 
2.1.4 Radiation delivery methods 
 Multiple methods are available for external beam radiation treatment. The first method 
of delivery developed for treatment was 2D conformal radiation therapy (2D-CRT). 2D-CRT has is 
directed by a 2D location of the tumor and radiation is delivered from 1 or more points, typically 
from an X-ray [24]. 2D-CRT delivers the most radiation to surrounding tissue, but is still sees use 
as palliative treatment for end stage metastatic cancers. 3D conformal radiation therapy (3D-
CRT) is more advanced and typically guided by a 3D image of the tumor from a CT scan or MRI. 
3D-CRT is the most commonly used form of external beam radiation treatment and is ideal for 
tumors that are immobile. Stereotactic body radiation therapy (SBRT) is a third method 
developed for radiation therapy. SBRT is treatment guided and adjusted in real time by a 3D 
image of the tumor through CT or ultrasound, which allows for high specificity of radiation dose 
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[25]. SBRT allows for great precision and reduces radiation dose to surrounding tissue due to its 
high specificity. SBRT has allowed for much more precise treatment of inoperable, moving 
tumors such as those in the lungs and heart. 
2.2  Lung cancer 
2.2.1 Lung cancer causes and development 
Lung cancer is one of the most understood cancers in terms of epidemiology. It has 
been linked to carcinogens in smoking as well as exposure to radon gas and pollution [4]. 
Despite this knowledge, lung cancer continues to be a common and aggressive form of cancer, 
accounting for 13.3% of new cancer cases while also accounting for 26.5% of cancer deaths [4]. 
2.2.2 Lung cancer classification 
Lung cancer is divided into multiple types and stages. The main two primary types are 
small-cell lung carcinomas (SCLCs) which make up 10% of diagnoses and non-small cell lung 
carcinomas (NSCLCs) which encompasses the remaining 90%. SCLC is further divided into small 
cell carcinoma and combined small cell carcinoma. NSCLC includes squamous cell carcinoma, 
large cell carcinoma and adenocarcinoma[4]. Stages of lung cancer include formation of cancer 
(stage I), cancer spreading to lymph nodes (stage II), cancer spreading to lymph nodes in upper 
bronchus (stage) III and cancer metastasizes outside the lung  (stage IV) [26]. 57% of lung cancer 
is diagnosed once cancer has metastasized, which leads to limited treatment options. 
2.2.3 Lung cancer treatment 
Lung cancer is difficult to treat with surgery as tumors can not always be removed 
effectively. This has led to non-invasive treatments of radiation therapy and chemotherapy 
being the primary treatments for the disease. SCLC is characterized by faster growth and more 
aggressive progression towards metastasis than NSCLC [27]. Due to having a more aggressive 
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disease path, SCLC standard treatment involves high dose chemotherapy, high intensity 
radiation, and multiple cisplatin regiments [28]. NSCLC has a better expected outcome than 
SCLC and in early stages multiple treatment options are available including thoracoscopic 
surgery to remove tumors [29]. 
2.2.4 Radiation induced pneumonitis  
Radiation dosing is limited in lung cancer treatment due to increased risk for 
development of pneumonitis and fibrosis. At higher levels of radiation dose per volume, an 
increased amount of fibrotic tissue forms in the lungs [30]. This risk of development of fibrosis is 
measured by mean lung dose and V20 [31]. V20 is defined as there percentage of volume of the 
lung receiving 20 Gy of radiation or more. When 2D-CRT and 3D-CRT are employed for 
treatment, a V20 of the patient’s lung is kept below 22%, as risk for pneumonitis and fibrosis 
greatly increases above this threshold [32, 33] Using SBRT, lower fractionalization is used at 
higher intensities so V20 is kept below 7% in clinical treatment to reduce these same risks [34]. 
The pneumonitis toxicities risk peak at 71 days [33] and it is imperative to reduce these 
immediate problems, but higher dose radiation is ideal for long term survival for patients with 
locally advanced NSCLC [5, 35]. 
2.3  Reactive oxidative species 
2.3.1 Reactive oxidative species in cell cycle 
 Reactive oxidative species (ROS) are naturally occurring elements in cells, produced by 
mitochondria and other organelles. ROS are radicals that cause DNA damage, protein damage 
and lipid damage which are naturally produced by cells and scavenged when at equilibrium [35]. 
Aside from damaging effects at high levels, ROS play an important role in directing cellular 
differentiation, proliferation, apoptosis and migration [36]. The generation of ROS is a favorable 
  
9 
 
response to pathogens and other negative stimuli in most cases as it triggers an immune 
response to resolve the problem.  
Oxidative stress occurs when there is an elevated level of free radicals in a system that is 
not resolved and leads to cellular dysfunction. This can come from sources such as a metabolic 
disease, neurodegenerative disease or an acute injury such as or radiation damage [37, 38]. 
Additionally, dysfunctional cells such as cancer cells have been found to be in a constant state of 
elevated oxidative stress [39]. 
2.3.2 Antioxidants 
 Antioxidants are species that are able to scavenge free radicals and reduce the oxidative 
stress of a system. Antioxidants can either be enzymes or small molecules [40]. They can be 
produced naturally by the body or derived from alternative sources. Small molecule antioxidants 
have been of greatest interest as treatments due to their ability to scavenge multiple types of 
free radicals and simpler delivery. 
Antioxidant supplement treatments have been proven effective in multiple studies. The 
antioxidant H2 has been shown to effectively reduce radiation induced lung damage [41], Trolox 
has proven to be an effective antioxidant to suppress nanoparticle induced oxidative stress [42], 
Quercetin suppresses oxidative stress in multiple models [43, 44], Resveratrol, another potent 
antioxidant has been applied in many studies [45, 46] and Curcumin has been shown to reduce 
ROS generation in multiple instances [47-49]. 
2.4  NF-κB  
 A major component of curcumin’s activity profile is its ability to downregulate NF-kB. [9, 
50]. NF-κB is a transcription factor that regulates many cytokines and adhesion molecules [51]. 
The components of this transcription factor include p50, p52, p65, REL and RELB proteins. These 
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proteins are phosphorylated in the cytoplasm and migrate to the nucleus where they begin a 
cascade which results in transcription of DNA, these transcriptions lead to expression of 
proinflammatory cytokines such as TNF-α and IL-1 [52]. 
2.5  Inflammation 
 Inflammation is the body’s natural response to pathogen or foreign invasion. 
Inflammation is characterized by first detection of the foreign invasion through antibody 
detection, oxidative stress or another cellular indication of pathogen [53].  
This is followed by cellular mechanisms such as NF-kB which will express 
proinflammatory cytokines including IL-1, IL-8 and TNF-α [54].  After expressing these 
proinflammatory cytokines, endothelial cells will induce expression of cellular adhesion 
molecules on their surface. Cellular adhesion molecules such as ICAM-1 and VCAM-1 are 
expressed on the surface of the cell, facilitating the recruitment of leukocytes and macrophages 
to the site of injury as well as promoting vasodilation [55].  
The acute inflammation begins as monocytes and neutrophils are recruited to the site 
and phagocytose the offending pathogen. If the injury is not able to be resolved, macrophages 
are recruited to the site. Macrophages act in many roles, including facilitating phagocytosis, 
increasing local levels of oxidative stress, inducing angiogenesis and producing extracellular 
matrix [56]. This production of extracellular matrix can be used to encapsulate the foreign body 
in fibrotic tissue and isolate it from the rest of the body [57]. If the injury is not localized to a 
discrete object though, widespread fibrosis of the tissue can occur which leads to many chronic 
inflammatory disease states such as pneumonitis [58].  
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2.6  Curcumin 
2.6.1 Curcumin structure and properties 
Curcumin is a natural phenol molecule derived from turmeric known for its anti-oxidant, 
anti-inflammatory and anti-cancer properties. Curcumin contributes to the orange color of 
turmeric and has a strong absorption peak at 420 nm. Curcumin is a strong antioxidant [48] and 
potent anti-inflammatory, downregulating pro-inflammatory cytokines including IL-6, IL-8 and 
TNFα [59]. Due to these properties, curcumin has been investigated as a chemosensitizer [60, 
61], radiosensitizer [62-64] and neuroprotective agent [65, 66]. It has been purported as an anti-
cancer drug as well due to anti-angiogenic effects [47], pro-apoptotic effects [67, 68] and anti-
proliferative effects [68-70]. 
 High dosing of curcumin is also relatively safe, as no toxicities from an oral dose of 
curcumin at 12g per day in humans was observed. The limiting factor in maximum oral curcumin 
dosing was patient compliance [71]. Curcumin has repeatedly exhibited poor bioavailability 
however, owing to its low absorption in the GI tract, rapid metabolism and rapid elimination 
[72]. Curcumin has a short half-life in vivo, quickly reducing to components [73], 90% of 
curcumin degrades in 30 minutes at physiological conditions [9].  
2.6.2 Curcumin as a radioprotectant 
The radio sensitizing effects of curcumin on cancer cells in vitro has been observed in 
multiple studies [62, 74-76]. The radioprotective effect of curcumin is less understood but has 
been well documented in vivo studies. It is thought that the primary mechanism of radiation 
protection of healthy tissue is reduction of ROS and attenuated inflammatory response. When 
curcumin was given as oral dose to rats, a reduction of lung fibrosis was observed after full body 
X-ray radiation of 13.5 Gy [22, 23]. Another study rats which were fed an oral dose of curcumin 
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had multiple beneficial effects in protecting the ilium mucosa after abdominal gamma radiation 
of 5 Gy [77]. Rats given oral dose of curcumin showed reduced ROS levels in tissue after 3 Gy full 
body gamma radiation [78]. Curcumin protected against radiation induced cataracts in rats after 
15 Gy full body gamma radiation [79] and administration of liposomal curcumin reduced 
radiation pneumonitis after 25 Gy X-ray full body radiation [80]. Curcumin has shown to reduce 
apoptotic cells in rat ovaries after 8.3 Gy of whole body gamma radiation [81].  In human trials 
where the radiation dose to patients ranged from 42.6–50.4 Gy, oral dose of curcumin has 
shown to reduce radiation induced dermatitis [82]. 
2.7  Poly(beta-amino esters) 
 PBAE are synthesized through an addition reaction between amines and acrylates. This 
reaction is an energetically favorable process where the acrylate and amine undergo a Michael 
addition, creating an ester bond between the two molecules. Use of primary amine and 
diacrylate molecules creates a linear PBAE, while networked polymer is produced from use of 
multifunctional amine or acrylates in synthesis.  
PBAE have been of interest for a variety of applications due to the tune-ability of the 
polymer class. Hundreds of acrylates and amines can be chosen from to adjust polymer 
properties such as length, charge, connectivity, degradation properties and toxicity [83, 84]. 
Linear PBAE have seen significant study in gene delivery due to their cationic properties. The 
cationic polymer is able to condense anionic DNA into nanoparticles and act as a degradable 
delivery vehicle[85].  Another area of interest in PBAE is crosslinked gels. These PBAE gels can be 
tuned  to control degradation and have applications as biomaterials [86] and delivery of 
hydrophobic drugs [87]. 
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 In this work curcumin was acrylated to form curcumin multiacrylate. This presents a 
unique application where the active drug is built into the PBAE delivery vehicle. The active 
curcumin is preserved until release upon the breaking of the ester bond in the polymer.  This 
PBAE system can then be tuned for degradation properties though selection of primary amines.
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Chapter 3: Research Goals 
3.1  Introduction 
The aim of this thesis was to develop a curcumin nanoparticle system that could be 
targeted to the lung vasculature through intravenous injection. A radiation injury model was 
developed and curcumin was tested to determine the amelioration of radiation damage to 
healthy cells. Curcumin poly(beta-amino ester) was synthesized and characterized in order to 
understand the chemical makeup and properties. HPLC and GPC was used to determine 
curcumin content and molecular weight. FTIR was performed to determine molecular 
components in the polymer. DSC provided insight into the glass transition temperature of the 
polymer. CPBAE nanoparticles were synthesized and the size stability and degradation 
properties of these nanoparticles were studied. Oxidative stress plays a critical role in both lung 
carcinoma and healthy lung cell death. By delivering degradable curcumin nanoparticles to the 
lungs, oxidative stress in healthy cells may be able to be reduced and toxicity from radiation can 
be attenuated. 
3.2  Objectives and Significance 
The overall hypothesis of this work is: 
Linear curcumin poly(beta-amino ester) polymer can be synthesized and used to form 
nanoparticles for targeted release of curcumin that scavenge free radicals and influence 
radiation response of both cancer cells and healthy tissue. 
3.2.1  Specific Aim 1: Develop a radiation damage model and evaluate curcumin’s effect 
on cellular injury 
A. Characterize damage to human umbilical vein endothelial cells from gamma radiation 
developed by a Cs-137 irradiator. 
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B. Introduce curcumin to radiation damage model and assess change in Calcien AM 
Orange-Red viability, DCF-DA fluorescence and γ-H2AX foci formation. 
3.2.1.1 Hypothesis 1 
Using radiation damage model developed, curcumin will reduce oxidative stress in 
irradiated cells, increasing viability and reducing γ-H2AX foci formation. 
3.2.1.2 Significance and Outcome 
Experiments outlined and carried out in chapter 4 test this hypothesis. A radiation 
model protocol was successfully developed that quantified radiation damage to human 
umbilical vein endothelial cells. Curcumin was shown to reduce the viability of irradiated cells in 
a dose dependent manner, while trolox at all concentrations tested had no effect of cell 
viability. Curcumin and trolox were shown to decrease DCF fluorescence after radiation damage 
indicating reduction in radiation damage. When the cellular response in cells was evaluated in 
the γ-H2AX foci formation assay, no protection in DNA breaks was found.  
3.2.2 Specific Aim 2: Synthesis and characterization of linear CPBAE 
A. Synthesize linear CPBAE and characterize using Gel Permeation Chromatography (GPC), 
High Performance Liquid Chromatography (HPLC), Differential Scanning Calorimetry 
(DSC) and Fourier Transformed Infrared Spectroscopy (FTIR) 
B. Develop CPBAE nanoparticles with size and stability relevant for intravenous drug 
delivery 
C. Characterize degradation of curcumin poly(beta-amino ester) in bulk polymer and in 
nanoparticles 
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3.2.2.1 Hypothesis 2 
Utilizing a Michael addition reaction between curcumin diacrylate and an amine, 
curcumin poly(beta-amino ester) can be synthesized into a linear polymer which 
can degrade and release curcumin to exert therapeutic effect. 
3.2.2.2 Significance and Outcome 
Experiments outlined and carried out in chapter 5 test this hypothesis. A Michael 
addition reaction method was used to produce curcumin poly(beta-amino ester). CPBAE 
composed of CMA and IBA was synthesized and characterized with GPC, HPLC, DSC and FTIR. 
These tests positively indicated polymerization during the reaction. Nanoparticles were 
synthesized using the developed CPBAE and were able to be size controlled for the desired 
application of intravenous delivery. Nanoparticles were found to be stable but degraded very 
slowly through hydrolysis. Both the CPBAE nanoparticles and bulk CPBAE polymer only released 
a maximum of 20% of the theoretical yield.  
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Chapter 4: Curcumin and Effect on Radiation Damage 
4.1 Introduction 
Radiation oncology has seen significant advances over the past 100 years which have led 
to better treatment for a variety of cancers including skin cancer, larynx carcinoma, lymphoma, 
head and neck cancers, prostate cancers, lung cancer and breast cancer [3]. Developments in 
radiation technology aim to increase the dose of radiation to tumor sites and reduce the 
amount delivered to surrounding tissue [3]. Recent technologies such as stereotactic body 
radiation therapy (SBRT) have made radiation dosing even more precise, which has allowed for 
greater selectivity in treating tumors [88].  Although doses of radiation are now more precise, 
peripheral toxicities are still the factor that limits the amount of radiation that can be 
administered [5, 89, 90]. It is still desirable to deliver higher amounts of radiation to better kill 
tumor cells though [91] and to achieve this end, radioprotectors, molecules that exert a 
differential protective effect on healthy tissue over cancer cells have been investigated. 
Amifostine is currently the only radioprotector that has been approved by the FDA for use in this 
manner [92]. Although Amifostine has seen success in clinical trials [93], there are significant 
drawbacks including increased nausea, hypotension and limited time of protection for 
Amifostine after delivery [94, 95].  
Curcumin is one molecule that has been of interest for use as a radioprotectant. 
Curcumin is a natural phenol molecule with anti-oxidant and anti-cancer properties [9]. 
Curcumin has been shown to be safe in clinical trials, including as free curcumin [10] and 
delivery in liposomal form [11]. High dosing of curcumin is also relatively safe, as no toxicities 
from an oral dose of curcumin at 12g per day in humans was observed. Curcumin had a low rate 
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of uptake in the GI tract and the limiting factor in maximum oral curcumin dosing was patient 
compliance [71]. 
Curcumin has been shown to be effective as a radioprotector in multiple studies. When 
curcumin was given as oral dose to rats, a reduction of lung fibrosis was observed after full body 
X-ray radiation of 13.5 Gy [22, 23]. Rats which were fed an oral dose of curcumin had multiple 
beneficial effects in protecting the ilium mucosa after abdominal gamma radiation of 5 Gy [77]. 
Rats given oral dose of curcumin showed reduced ROS levels in tissue after 3 Gy full body 
gamma radiation [78]. Curcumin protected against radiation induced cataracts in rats after 15 
Gy full body gamma radiation [79] and administration of liposomal curcumin reduced radiation 
pneumonitis after 25 Gy X-ray full body radiation [80]. Curcumin has shown to reduce apoptotic 
cells in rat ovaries after 8.3 Gy of whole body gamma radiation [81].  In human trials where the 
radiation dose to patients ranged from 42.6–50.4 Gy, oral dose of curcumin has shown to 
reduce radiation induced dermatitis [82]. 
Curcumin’s radioprotective effect is thought to be due to its reduction of oxidative 
stress and inhibition of transcription of genes related inflammation in healthy cells [96]. Its 
radiosensitization of cancer cells has been linked to its upregulation of nuclear factor Kappa-
Beta (Nf-kB), promoting apoptosis in cancer cells [96] 
The radio sensitizing effects of curcumin on cancer cells in vitro has been observed in 
multiple studies [62, 74-76]. The radioprotective effects of curcumin have been demonstrated in 
both clinical and animal models as described above, but in vitro studies have not been as clear 
cut. Curcumin has not been shown to increases viability of any healthy cell line. In fact, curcumin 
tends to reduce viability of healthy cells on its own [97]. This indicates that curcumin may not be 
radioprotecting primarily through antioxidant capacity of curcumin as theory suggests.  
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4.2 Methods and Materials: 
4.2.1 Reagents 
All reagents were received and used as delivered. 2’, 7’-dichlorodihydrofluorescein 
diacetate (DCF-DA) was purchased from Invitrogen. Calcien AM red-orange was purchased from 
life technologies. Single donor HUVECs, EGM-2 culture media and pen-strep was purchased from 
Lonza. Curcumin was purchased from Chem-Impex International, Inc and trolox was purchased 
from Sigma Aldrich.  
4.2.2 Irradiation Conditions 
University of Kentucky radiation facility’s Shepherd Model Mark I-30 Cs-137 irradiator 
was used for dosing cells with radiation. Irradiation was performed at room temperature with 
rotation to ensure an even dose across well plates. Gamma radiation was delivered at a rate of 
4.4 Gy/min to deliver doses ranging from 2-20 Gy. 
4.2.3 Cell Culture Preparation Conditions 
HUVEC were propagated and cultured at 37°C at 5% CO2 and 95% Humidity. Lonza EGM-
2 culture media with penicillin and streptomycin was changed 24 hours after seeding into a new 
flask and every 48 hours. HUVEC seeded in well plates had media changed every 48 hours as 
well unless otherwise specified. 
4.2.4 Confluent Cell Viability Model 
HUVECs were seeded in a 96 well plate and cultured overnight to confluency. Cells were 
then irradiated using the Shepherd Model Mark I-30 Cs-137 irradiator and then incubated. A 
Calcien AM live assay was then performed to assess the viability of the cells at each Time points 
0, 1, 2, 3, 5 and 10 days after radiation. Cells were washed twice with warm media followed by 
the addition of 2μM Calcien AM in Media. The well plate was then incubated for 1 hour. The 
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wells were then washed twice more in warm media. The fluorescence was read on the Synergy 
MX plate reader (540 nm excite, 590 nm emission). 
4.2.5 Cell Proliferation 
HUVECs were seeded in 96 well plates and cultured for 24 hours. The cells were then 
treated with either free curcumin or free trolox and were incubated for 1 hour. Cells were then 
irradiated using the Shepherd Model Mark I-30 Cs-137 and cultured for 72 hours. A Calcien AM 
live assay was then performed to assess the viability of the cells. Cells were washed twice with 
warm media followed by the addition of 2μM Calcien AM in Media. The well plate was then 
incubated for 1 hour. The wells were then washed twice more in warm media. The fluorescence 
was read on a Synergy MX plate reader (540 nm excite, 590 nm emission). 
4.2.6 Cell ROS Generation 
HUVECs were seeded in 96 well plates at 20,000 cells/cm2 and cultured for 24 hours. 
The cells were then treated with 5 µM of DCF-DA and either free curcumin or free trolox. Cells 
were then incubated for 1 hour. After incubation, the plates were then irradiated using the 
Shepherd Model Mark I-30 Cs-137 and cultured for 24 hours. Fluorescence reading of the cells 
was taken at the 24 hour time point after radiation. Plates were read on a Synergy MX plate 
reader at 485 nm excitation, 530 nm emission. 
4.2.7 Cell γ-H2AX foci Formation Assay 
HUVEC were seeded in 4 chambered chamber slides at 50,000 cell/cm2 and incubated 
for 24 hours. Two chamber slides were then pretreated with 1µg/mL curcumin and incubated 
for an hour. The other two chamber slides had their media changed. The chamber slides were 
then incubated for 1 hour. One of the curcumin incubated chamber slide and one with media 
chamber slide was irradiated at 20 Gy. The chamber slides were then washed in warm PBS once. 
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A half an hour after radiation, the slides were fixed in 3.7% formaldehyde in PBS for 20 minutes. 
The chamber slides were then washed twice more in warm PBS. Immunofluorescence staining 
was then performed and images of cells were taken using fluorescent microscopy. 
4.3 Results 
4.3.1 Development of Radiation Model 
Lung tissue is highly vascularized and endothelial cells are a priority for radiation 
protection. Endothelial cells are susceptible to oxidative stress and are actively involved in 
recruiting leukocytes. Due to this, HUVEC were selected as a cellular system to evaluate damage 
to the healthy endothelium surrounding tumors. No systematic model is present in the 
literature using these cells to evaluate radiation damage however. The response of these cells to 
radiation was investigated in order to develop a meaningful assay. 
HUVECs were seeded at confluency and treated with 0 Gy, 20 Gy or 40 Gy dose of 
radiation. Viability of cells was measured over ten days. Viability results were normalized to the 
percent viability of the 0 Gy control of that day. Only a small difference in viability was seen in 
irradiated cells at early time points, indicating no acute damage through this Calcien AM viability 
assay. There was also no observable difference in viability between 20 Gy and 40 Gy irradiated 
cells as well. Even 5 days after radiation, the radiation groups had 60% of the fluorescence 
values of non-irradiated cells. This delayed effect on viability was possibly due to cell wash off of 
irradiated groups and no healthy cells can proliferate to replace them. This data indicates that 
even at high radiation doses the mechanism of damage to cells is still through reduction of 
proliferative ability. 
In order to observe radiation damage to cells in a proliferative environment, cells were 
seeded subconfluent at 10,000 cells/cm2, 20,000 cells/cm2 and 40,000 cells/cm2. Cells were then 
radiated and viability was measured 72 hours later using Calcien AM. No significant difference 
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between the 20 Gy and 40 Gy irradiated groups was measured, but cells seeded at 10,000 
cells/cm2 had 43% the viability of non-irradiated cells, 20,000 cells/cm2 had 69% the viability of 
non-irradiated cells and 40,000 cells/cm2 had 72% the viability of non-irradiated cells. Although 
10,000 cells/cm2 seeding density showed the greatest difference in viability between irradiated 
cells and non-irradiated cells, 20,000 cells/cm2 seeding density was chosen for the radiation 
model due to highest experimental consistency. 
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Figure 4-1: HUVEC viability radiation response N=4. Error bars represent standard error. * 
indicates p-value<0.05 in two-way ANOVA. (A) HUVEC radiation injury model: HUVEC were 
treated with radiation and normalized to percent of non-irradiated values at each time point (B) 
HUVEC viability 3 days after radiation as a function of cell seeding density. Control group was 
considered the group with no radiation for each cell density. 
4.3.2 Viability of cells after proliferating 
The viability of the proliferating cells were measured to determine the effect 
antioxidants and radiation had in the model. Antioxidant concentrations ranging from 0-
10µg/mL were incubated for 1 hour with cells before radiation. 72 hours after radiation, a 
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Calcien AM live assay was performed. Cells recieving 20 Gy exhibited 74% viability of non-
irradiated cells. Cells treated with trolox had no significant effect on viability as viability 
remained constant as trolox concentration increased. When cells were pretreated with 
curcumin, lower viabilities were observed as concentration increased. When cells were treated 
with both curcumin and radiation the resulting viability was lower than either one individually. 
This data indicates that curcumin inhibits cell proliferation and it is not a function of its 
antioxidant capacity as trolox has no effect even at concentrations greatly above 10µg/mL.  
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Figure 4-2: HUVEC pretreated with Curcumin/Trolox radiation viability response 72 
hours after radiation. Cells seeded at 20,000 cells/cm2. N=4. Error bars represent standard error. 
* indicates p-value<0.05 in two-way ANOVA. (A) HUVEC viability as function of curcumin 
concentration and radiation dose (B) HUVEC viability as function of trolox concentration and 
radiation dose 
4.3.3 Inhibition of ROS generated by radiation 
The effect of antioxidants on the irradiated system’s ROS generation was measured 
using DCF-DA. Antioxidant concentrations ranging from 0-10µg/mL were incubated for 1 hour 
with cells before irradiation. 24 hours after radiation, a DCF fluorescence reading was 
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performed. Cells treated with only radiation exhibited 124% of control DCF fluorescence. 
Addition of curcumin to radiated cells reduced this fluorescence to 61%, 14% and 14% of control 
respectively for 1 µg/mL, 5 µg/mL and 10 µg/mL curcumin treatment. A similar trend was seen 
with trolox where addition of trolox to radiated cells reduced this fluorescence to 67%, 43% and 
35% of control respectively for 1 µg/mL, 5 µg/mL and 10 µg/mL trolox treatment. This indicates 
that both curcumin and trolox are reducing ROS generated by radiation as expected. DCF-DA 
assay takes into account background fluorescence from DCF in the media however so it may not 
accurately portray damage to the individual cells. It should also be noted that the DCF 
fluorescence is especially low for curcumin at 5 µg/mL and 10 µg/mL concentrations. This is due 
to cell death from curcumin which halts cellular respiration and ROS generation. 
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Figure 4-3: HUVEC pretreated with Curcumin/Trolox, radiation DCF fluorescence 
response 24 hours after radiation. Cells seeded at 20,000 cells/cm2. N=4. Error bars represent 
standard error. * indicates p-value<0.05 in two-way ANOVA. (A) HUVEC DCF fluorescence as 
function of curcumin concentration and radiation dose (B) HUVEC DCF fluorescence as function 
of trolox concentration and radiation dose 
4.3.4 Cell γ-H2AX foci Formation Assay 
γ-H2AX foci formation assay was preformed to gauge cellular response and eliminate 
possible background effects from media. Confluent HUVEC were prepared in chamber slides. 
One group received no treatments, another received 1µg/mL curcumin treatment, another 
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received 20 Gy radiation treatment and the last received 1µg/mL curcumin and 20 Gy radiation 
treatment. The chamber slides were fixed, stained and imaged using fluorescent microscopy. 
Few cells exhibited γ-H2AX foci formation in groups without radiation treatment. Both the 20 Gy 
radiation treatment groups exhibited many γ-H2AX foci formations though, indicating severe 
DNA damage. The cells pretreated with curcumin before radiation had no reduction in γ-H2AX 
foci formations compared to cells only treated with radiation though. This shows that curcumin 
has no significant effect on DNA damage in this system. This lack of cellular response to 
curcumin could also be due to extreme experimental conditions as 20 Gy of radiation 
completely saturates the cells with activated histones. 
 
Figure 4-4: HUVEC pretreated with Curcumin, radiation γ-H2AX foci formation 
response (A) no treatment (B) curcumin treatment (C) radiation treatment (D) curcumin and 
radiation treatment 
4.4 Discussion 
The experiments carried out in this chapter were successful in creating a radiation 
damage model and characterizing curcumin’s interaction with radiation in healthy endothelial 
cells. Curcumin showed reduction in ROS generation in irradiated cells but in a viability assay, 
curcumin was shown to be toxic to the cells and further reduced the viability of irradiated and 
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non-irradiated cells alike. Curcumin also showed no measureable effect on the amount of 
double stand breaks created from radiation dame in radiated cells. This data shows that simply 
adding antioxidants to an endothelial layer model to reduce ROS does not lead to an increase in 
viability of cells, as curcumin did not show any protection in radiation damage. This indicates 
that curcumin’s role as a radioprotectant may not be directly a function of its antioxidant 
capacity and is dependent on factors outside of an endothelial monolayer in vitro model. 
Although this result does not change the conventional thought of how curcumin radioprotects. 
This data suggests that an endothelial layer does not see much benefit from antioxidant 
treatment before radiation. Due to all the in vivo curcumin radioprotection data in the 
literature, this would mean curcumin requires a more complex environment to exert a 
protective effect. 
As mentioned previously, the reduction in ROS in the cells seen by curcumin in the DCF 
assay may be over reported as the media surrounding the HUVEC contributes to fluorescence 
levels. The radiation dosing of cells may not have been ideal for γ-H2AX foci formation assay as 
well. It would have been beneficial to use a lower radiation dose so all the cell histones were not 
saturated. Even if the curcumin was exerting a protective effect, a measureable effect could not 
be measured at this damage level. A lower dose of 5 Gy may have been better suited than the 
20 Gy treatment. 
4.5 Conclusions 
A radiation damage model was successfully developed using a HUVEC monolayer of 
cells. The in vitro effect of gamma radiation on HUVEC pretreated with curcumin was 
characterized. Cells treated with curcumin showed significantly less ROS development than both 
their radiated and non-radiated respective controls. Cells treated with curcumin showed a 
decrease in viability for both radiated and non-radiated cells. Curcumin pretreatment exhibited 
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no reduction in γ-H2AX foci formation in cells after radiation damage. These results provide 
insight into the radioprotective mechanism of curcumin, as the antioxidant capacity has not 
shown to play a large role in reduction of toxicity or DNA damage to healthy cells in this model. 
  
31 
 
Chapter 5: Synthesis and Characterization of Curcumin Polymer 
5.1 Introduction 
Curcumin has been shown to have a low absorption rate, is readily metabolized and 
quickly excreted from the body [98-101].  A variety of delivery mechanisms have been tested 
including liposomal curcumin,  structural modification of curcumin and curcumin nanoparticles 
to address these pitfalls and deliver active curcumin to the site of interest. Liposomal curcumin 
has been shown to have at least equal efficacy in biodistribution as free curcumin[102] and is 
able to load more curcumin in cells than aqueous-DMSO delivered curcumin[103]. A curcumin 
analogue, EF-24 was developed and distribution was tested in mice. This molecule had similar 
activity to curcumin and possessed a longer half-life and lower plasma clearance compared to 
free curcumin[104]. Cross linked micellar curcumin nanoparticles synthesized with N-
isopropylacrylamide, N-vinyl-2-pyrrolidinone and poly(ethyleneglycol) acrylate have been 
synthesized in a size range below 100 nm and possessed similar efficacy as curcumin in vivo and 
in vitro [105]. Each of these methods was able to increase the amount of curcumin delivered 
when compared to free drug, but better targeting and protection of molecular curcumin is 
needed. 
In order to address this, a Michael addition reaction to form a linear poly(beta-amino 
ester) (PBAE) was chosen as the method to polymerize curcumin into a functional vehicle for 
extended release. Poly(beta-amino ester) chemistry employs ester bonds that can be 
hydrolytically degraded. This incorporation of curcumin into the polymer is promising, as the 
active curcumin is preserved until release upon the breaking of the ester bond in the polymer.  
PBAE systems are able to be tuned through choice of acrylates and amines to influence both 
degree of polymerization and degradation rate as well.  Networked polymers can also be 
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produced though increasing the number of functional groups in the molecules used beyond a 
1:1 ratio. Linear PBAE has the advantage that it can be used to develop nanoparticles with 
targeting antibody coatings. 
Curcumin was functionalized into CMA through methods developed by the lab.  Primary 
amines were bought commercially and used for polymerization in order to develop a near linear 
polymer as the CMA developed is thought to consist mostly of curcumin diacrylate. Through 
adjustment of reaction conditions a CPBAE polymer can be synthesized and formed into 
targeted nanoparticles. These particles will be able to degrade, releasing curcumin to exert its 
therapeutic effect. 
5.2 Methods and Materials 
5.2.1 Reagents 
 All solvents were obtained from Sigma-Aldrich or Fisher Scientific. Curcumin was 
purchased from Chem-Impex International. Acryloyl chloride was purchased from Sigma-Aldrich. 
All acrylates and amines were purchased from Sigma-Aldrich. PLGA was purchased from 
DURECT. 
5.2.2 Synthesis and characterization of Curcumin Multiacrylate 
5.2.2.1 CMA Synthesis Methods 
Curcumin Multiacrylate (CMA) was synthesized using protocol developed by our lab in 
which curcumin is reacted with acryloyl chloride. Briefly, curcumin was dissolved in anhydrous 
tetrahydrofuran (aTHF) in a three-neck round bottom flask. Triethylamine (TEA) is then added to 
the solution and the flask is purged with N2 gas. Acryloyl chloride is added to the solution and 
the reaction is then allowed to proceed in darkness overnight. To purify the curcumin 
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multiacrylate product, first TEA-HCl salt is removed using filter paper. THF is then evaporated 
from the solution using a vacuum pump.  
After evaporation, a solid product is recovered. This product is dissolved in anhydrous 
Dichloromethane (aDCM). In order to remove more TEA in the product, an equal volume of 
0.1M HCl was added to this solution, mixed and then centrifuged. The organic phase of 
CMA+DCM was collected after centrifugation. Next, excess acrylic acid must be removed. An 
equal volume of 0.1M K2CO3 is added to this CMA+DCM solution, mixed and then centrifuged. 
The organic CMA+DCM phase is collected. 
In order to remove residual water MgSO4 is added to the CMA+DCM solution until 
bubbles are no longer seen escaping. The solution is filtered to remove MgSO4 salt. The 
CMA+DCM solution placed under a vacuum to remove DCM from the solution. The final CMA 
product is collected and stored at -80ᵒC. 
5.2.2.2 CMA HPLC Characterization 
A 1 ml solution of CMA was prepared in acetonitrile at a concentration of 100µg/ml. 
This sample was run through the HPLC system with a changing gradient methodology. The 
injection volume was 50 µL.  The method begins 50% acetonitrile and 50% aqueous solution. 
The aqueous solution decreases to 0% over 15 minutes and then remains constant for 5 
minutes. The aqueous solution concentration then increases to 50% over 5 minutes. The 
concentration then remains constant at 50% aqueous for 5 minutes until the method completes 
at a 30 minute run time. The elution times of material is depicted in a chromatogram at both 
210nm and 420nm wavelengths. 
5.2.2.3 CMA GPC Characterization 
A 1 mL solution of CMA was prepared in THF at a concentration of 5mg/mL. A Shimadzu 
Providence LC-20 AB HPLC with a refractive index sensor and UV Vis spectrometer with a 
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Polymer Laboratories 300 x 7.5 mm PLgel 3 µm mixed-E column system was used. This sample 
was run through the GPC with a 20µL injection volume. 
5.2.2.4 CMA Mass Spectrometry 
A 1mg/mL solution of CMA in anhydrous acetonitrile was prepared for use in mass 
spectrometry. A Thermofinnigan mass spectrometer model LTQ with a linear ion trap mass 
analyzer and electrospray ionization was used to characterize this sample. A spectra was 
produced in both positive ion and negative ion methodologies. 
5.2.2.5 CMA FTIR Characterization 
CMA was characterized using Fourier Transformed Infrared spectroscopy. A Varian 
Digilab stingray FTIR system with a 7000e stepscan spectrometer was used. Solid powder CMA 
was placed on the crystal and the software methods were used to produce a spectra. 
5.2.3 Synthesis and Characterization of Curcumin Poly(beta-amino ester)  
5.2.3.1 Adjustment of Amine and Solvent Poly(beta-amino ester) 
Preliminary CPBAE synthesis was performed using aDCM and MEK as a solvent for CMA. 
Trials were performed using 50mg CMA with a 1:1 molar ratio of primary amine. Isobutylamine 
(IBA), N,N’‐Dimethyl‐ 1,3‐propanediamine (NNDA) and methoxypolyethylene glycol amine 
(MEO) were chosen to test as amine groups. 50 mg of CMA and 100µL of solvent were added 
into each vial and vortexed. The appropriate amine was then added under the hood and stirred 
at 60°C for 24 hours. Reactions were then solubilized in THF and characterized using GPC. 
5.2.3.2 Precipitation of Curcumin Poly(beta-amino ester) 
CPBAE was synthesized at a 1:1.5 molar ratio of CMA to IBA. CMA was solubilized in 
MEK at a concentration of 500mg/mL. IBA was added and the CMA-MEK solution and the 
reaction was heated to 60ᵒC, stirred and left to react for 24 hours. The polymer was collected 
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and dissolved in THF. The THF-CPBAE solution is then added into cold ethanol at a 1:10 
THF:ethanol volume ratio. The solution is then centrifuged at 4500 rpm at 4ᵒC for 1 hour. The 
supernatant is decanted and the CPBAE solid is freeze dried. GPC was used to determine the 
molecular weight of the polymer and its size distribution compared to CPBAE without 
precipitation. 
5.2.3.3 Adjustment of Molar Ratios of Acrylate to Amine 
Curcumin PBAE was produced at varying ratios of acrylate to amine in triplicate. With 
the assumption that CMA is 100% curcumin diacrylate, a range of reactions including 1:0.5, 1:1, 
1:1.5 and 1:2 molar ratio of CMA to IBA were produced. 50 mg of previously synthesized CMA 
was weighed into a glass vial. 100 µL of MEK was then added to each vial and vortexed until fully 
dissolved. The appropriate molar ratio of IBA was then added into each vial. A stir bar was then 
added to each vial, capped and then heated to 60°C and stirred for 24 hours. GPC was used to 
determine the molecular weight of the polymers. 
5.2.3.4 Adjustment of Acrylate and Reaction Rate Conditions Poly(beta-amino ester) 
Polymers were prepared in similar conditions to previous methods of CPBAE synthesis 
with added variables to influence reaction rate. These being the addition of 1,8-
Diazabicyclo[5.4.0]undec-7-ene (DBU) catalyst and increased temperature of 90°C compared to 
60°C. As well as adjusting reaction rate variables, acrylates including CMA, Polyethylene(glycol) 
diacrylate (PEGDA), Diethylene(glycol) diacrylate (DEGDA) and 1,6-Hexanediol diacrylate 
(HEXDA) were tested. 
Briefly, reagents were added into a vial with a stir bar and placed into an oil bath at 60°C or 
90°C. Each vial contained a total mass of 200 mg with a 1:1 acrylate to amine ratio. No extra 
solvent was added to reactions except for CMA groups which were solvated with MEK. DBU 
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catalyst was added at 50 mol% of amine used. Reactions were left to proceed for 24 hours with 
stirring.  
The product was then suspended in THF after 24 hours of stirring. A sample at a 
concentration of approximately 10 mg/ml was prepared and analyzed in the hydrophobic GPC 
column. 
5.2.3.5 SEM imaging Curcumin Poly(beta-amino ester) 
Curcumin poly(beta-amino ester) was synthesized at a molar ratio of 1:1.5 CMA:IBA and 
purified by precipitation in ethanol. CPBAE was suspended in acetone and placed on an SEM 
stub. The stub was left open to atmosphere to evaporate off the acetone. A Hitachi S-4300 with 
cold cathode field emission was used to produce images of the CPBAE. 
5.2.3.6 Solvent Cast Curcumin Poly(beta-amino ester) Films 
1:1.5 CPBAE and 50,000 MW PLGA were both dissolved in DCM at a concentration of 1 
mg/mL. CPBAE solution and PLGA solution were mixed to various ratios of CPBAE to PLGA. The 
weight percent PLGA in the polymer was increased from 0 to 100 in increments of 20. Using a 
pipette, solutions were spread into films on glass slides and were left to evaporate overnight. 
5.2.3.7 Differential Scanning Calorimetry Curcumin Poly(beta-amino ester) 
Differential Scanning Calorimetry (DSC) was performed on solvent cast CPBAE-PLGA 
polymer films from 0wt% PLGA to 100wt% PLGA in increments of 20wt%. The method used 
preheated the sample to 55° C and cooled to -10°C in order to give all samples similar heating 
history before running the test. Heat flow was then characterized from -10° C to 150° C. The 
glass transition point was characterized as the minimum of the trough when the sample was 
heated. 
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5.2.3.8 FTIR Curcumin Poly(beta-amino ester) 
CPBAE was characterized using Fourier Transformed Infrared spectroscopy. A Varian 
Digilab stingray FTIR system with a 7000e stepscan spectrometer was used. Solid powder CPBAE 
was placed on the crystal and the software method was used to create a spectra. 
5.2.4 Curcumin Poly(beta-amino ester) Nanoparticle Synthesis 
5.2.4.1 Nanoparticle Synthesis Methods 
Nanoparticles were synthesized using a nanoprecipitation method. Both CPBAE and 
PLGA polymer were dissolved in acetone at a concentration of 5mg/mL. Experimental groups of 
pure CPBAE, pure PLGA and 30:70 wt% CPBAE:PLGA were chosen. 1 mL of the organic solution 
was added dropwise into 4 mL of DI while vortexing at 2000 rpm. Acetone was then removed 
from the suspension under a vacuum pump. 
5.2.4.2 Dynamic Light Scattering (DLS) Size Characterization 
PLGA nanoparticles, CPBAE nanoparticles and 30:70 CPBAE:PLGA nanoparticles at a 
concentration of 1mg/mL in DI water were put into a cuvette. A Malvern Zetasizer Nano DLS was 
used to measure nanoparticle size. 
5.2.4.3 Nanoparticle Zeta Potential Characterization 
PLGA nanoparticles, CPBAE nanoparticles and 30:70 CPBAE:PLGA nanoparticles at a 
concentration of 1mg/mL in DI water were put into a cuvette. A Malvern Zetasizer Nano DLS was 
used to measure nanoparticle zeta potential. 
5.2.4.4 DLS Size Characterization of Nanoparticles Over Time  
30:70 CPBAE:PLGA nanoparticles at 1mg/ml concentration in DI water were prepared. A 
Malvern Zetasizer Nano DLS was used to measure nanoparticle size over time in 15 minute 
intervals. The chamber was kept at a constant 25ᵒC. 
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5.2.4.5 SEM Imaging of Nanoparticles 
30:70 wt% CPBAE:PLGA nanoparticles were synthesized using previous methods. 
Nanoparticles were suspended in acetone and placed on an SEM stub. The solution was left to 
evaporate of the acetone. A Hitachi S-4300 with cold cathode field emission was used to 
produce images of the particles. 
5.2.5  Release of Curcumin from Curcumin Poly(beta-amino ester) 
5.2.5.1 Solid Polymer Curcumin Release UV-Vis 
Freeze dried CPBAE solid was crushed and weighed to 50 mg of theoretical curcumin 
(74.5 mg CPBAE). The CPBAE was then added to 1 L of 0.1 wt% SDS PBS. This was stirred 
continuously at 37˚C and samples were taken at given time points. The samples were 
centrifuged at 10,000 rpm for 5 minutes. The supernatant was saved and measured in the UV-
Vis compared to a calibration curve of free curcumin at 420nm wavelength. 
5.2.5.2 Nanoparticle Curcumin Release UV-Vis 
Freeze dried CPBAE dissolved in acetone was added into 0.1wt% SDS in PBS. The final 
concentration of the solution was 74.5ug/ml cPBAE in 1wt% SDS in PBS (50 µg of theoretical 
curcumin). The stock solution was divided into 1 mL aliquots and each was placed in the 
agitating incubator at 37ᵒC. Vials were taken off at given time points and then centrifuged at 
10,000 rpm for 5 minutes. The supernatant was saved and measured in the UV-Vis compared to 
a calibration curve of free curcumin at 420nm wavelength. 
5.2.5.3 Nanoparticle Curcumin Release HPLC 
Pure CPBAE dissolved in acetone was added into 1wt% SDS in PBS. The final 
concentration of the solution was 74.5ug/ml CPBAE in 0.1wt% SDS in PBS (50 µg of theoretical 
curcumin). The stock solution was divided into 1 mL aliquots and each was placed in the 
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agitating incubator. Vials were taken off at given time points and then centrifuged at 10,000 rpm 
for 5 minutes. Measured curcumin standards were prepared in ACN and used as a calibration 
curve to determine the amount of curcumin in each supernatant.  
5.2.5.4 Nanoparticle Curcumin Release GPC 
Pure CPBAE dissolved in acetone was added into 0.1wt% SDS in PBS. The final 
concentration of the solution was 74.5ug/ml CPBAE in 0.1wt% SDS in PBS (50 µg of theoretical 
curcumin). The stock solution was divided into 1 mL aliquots and each was placed in the 
agitating incubator. Vials were taken off at given time points and then centrifuged at 10,000 rpm 
for 5 minutes. GPC was used to measure molecular weight of degraded CPBAE precipitate over 
time. 
With the similar conditions, CPBAE polymer was solubilized in acetone and then added 
into 0.1wt% SDS PBS for nanoparticle degradation trials. Samples were taken at time points and 
the entire solution was freeze dried. The solid recovered after freeze drying was dissolved in THF 
and characterized through GPC. GPC UV-Vis chromatograms at 420nm were developed for each 
time point. UV-Vis at 420nm was used to capture a chromatograph of curcuminoids as a 
function of elution time. 
5.3 Results 
5.3.1 Synthesis and Characterization of Curcumin Multiacrylate 
5.3.1.1 HPLC Characterization of CMA 
Curcumin Multiacrylate was synthesized and characterized using HPLC. The 
characteristic peak of curcumin at 8 minutes was not seen, indicating that the product only 
acrylated curcumin. As shown in the chromatogram (UV detector set at 420nm), a major peak 
was observed at 13 minutes elution time as well as two smaller peaks at 11.5 and 12 minutes. In 
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a second chromatogram (UV detector set at 210m), peaks were observed at 10.8, 11.5, 12 and 
13 minutes. On the HPLC chromatogram set at 420nm, the 13 minute peak is thought to be 
curcumin diacrylate while 11.5 and 12 minutes are thought to be curcumin monoacrylate or 
curcumin triacrylate. 
 
Figure 5-1: HPLC chromatogram CMA(A) 420nm HPLC chromatogram 100µg/mL CMA in 
acetonitrile (B) 210nm HPLC chromatogram 100µg/mL CMA in acetonitrile 
 
  
41 
 
5.3.1.2 GPC Characterization of CMA 
Curcumin Multiacrylate was synthesized and characterized using GPC. When the IR 
chromatogram is examined, a major peak is seen at 21 minutes elution corresponding to low 
molecular weight species below 500 molecular weight. This peak corresponds to free CMA 
species. A significant peak from 16 minutes to 20 minutes is also observed, this corresponds to 
species between 1000 and 10000 Mw. This indicates that CMA is not pure and has some side 
reaction product. A GPC chromatogram (UV detector set to 420m) shows that curcuminoids are 
present in the 16-20 minute elution peak as well as the expected 21 minute elution peak where 
CMA would be expected. This shows that significant CMA is polymerized or aggregated and is 
not accessible.  
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Figure 5-2: GPC chromatogram CMA (A) 420nm GPC chromatogram 5mg/mL CMA in THF (B) 
IR GPC chromatogram 5mg/mL CMA in THF 
 
5.3.1.3 Mass Spectrometry Characterization of CMA 
CMA was characterized using both negative ion and positive ion mass spectrometry. 
Positive ion spectra indicates strong peaks at 477 and 531 molecular weight. These peaks 
correspond to curcumin diacrylate and curcumin triacrylate respectively. Other peaks are 
observed in the lower spectrum as well as higher in the spectrum indicating multiple impurities 
in the CMA. Negative ion spectra indicates a very strong peak at 475 which corresponds to 
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curcumin diacrylate. Other species are observed above and below curcumin diacrylate but are 
much lower in relative abundance.  
 
Figure 5-3:Mass spectrometry spectra CMA (A) Mass Spectrometry CMA Positive Ion 
Spectra (B) Mass Spectrometry CMA Negative Ion Spectra 
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5.3.1.4 CMA FTIR Characterization 
CMA was characterized using FTIR. Significant points of interest are the 2800-3000 
range which indicates carboxylic acid and the 3500 sharp peak which represents a phenol group. 
There was no sharp peak observed at 3500, which indicates that the CMA did not have an 
abundance of phenol groups as would be expected in curcumin. Carboxylic acid groups should 
be present in the CMA and a weak peak is seen in the 2800-3000 range indicating such. 
 
Figure 5-4: CMA FTIR spectrogram 
 
5.3.2 Curcumin Poly(beta-amino ester) Synthesis 
5.3.2.1 Adjustment of Amine Poly(beta-amino ester) 
CPBAE reactions were collected and prepared for GPC characterization. Both MEK and 
DCM solvents for the CMA-IBA reactions produced polymer at a molecular weight of 2850 and 
2900 molecular weight respectively. The Reactions using NNDA and MEO all became crystalline 
solids and would not dissolve in THF or ACN. These did not produce polymer and could not be 
characterized using GPC. Based off of these results IBA was used as the primary amine in further 
polymerization experiments. 
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Table 5-1: Molecular weight of CPBAE as a function of reaction conditions 
 IBA NNDA MEO 
MEK 2850 No signal No signal 
DCM 2900 No signal No signal 
 
5.3.2.2 Precipitation of Curcumin Poly(beta-amino ester) 
GPC results showed that 1:1.5 CMA:IBA CPBAE that was not precipitated has a 
molecular weight of 2500 and a PDI of 5.7. Single precipitation in ethanol was found to have a 
molecular weight of 6600 with a PDI of 2.0. This change in molecular weight from precipitation 
can be seen in the change in the polymer’s low molecular weight fraction peak past 20 minutes 
in both UV-Vis and IR spectrograms from GPC. In the un-precipitated polymers (A) and (C) strong 
peaks are observed in the polymer’s low molecular weight fraction peak past 20 minutes. After 
the polymer was precipitated in ethanol, (B) and (D) weaker peaks were observed in the 
polymers low molecular weight elution time past 20 minutes. 
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Figure 5-5: CPBAE IR and 420nm UV Vis chromatogram(A) GPC 420 nm UV Vis 
Chromatogram 1:1.5 CPBAE unprecipitated (B) GPC 420nm UV Vis Chromatogram 1:1.5 CPBAE 
precipitated (C) GPC IR Chromatogram 1:1.5 CPBAE unprecipitated (D) Figure: GPC IR 
Chromatogram 1:1.5 CPBAE precipitated 
 
5.3.2.3 Adjustment of Molar Ratios of Acrylate to Amine 
GPC results showed that molecular weight of the resulting polymer increased as the 
molar ratio of IBA increased up to 1:1.5 and then began to decrease as the ratio increased to 
1:2. These ratios were calculated assuming that 100% of the CMA is diacrylate and as this is not 
the case as shown by previous data. This theoretical 1:1.5 ratio has a relative maximum 
polymerization so was chosen for further testing of the polymer. 
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Figure 5-6: GPC assessment of CPBAE average molecular weight  
 
5.3.2.4 Adjustment of Acrylate and Reaction Conditions Poly(beta-amino ester) 
IBA was found to be the only primary amine capable of polymerizing with CMA in 
previous polymerization reactions. Based off of this, multiple acrylates including CMA, HEXDA, 
DEGDA and PEGDA were all reacted with IBA at different reaction conditions including 
temperature change and addition of catalyst. This was done in hopes to see if copolymer 
formation with CMA and another acrylate could be produced at a later point. CMA-IBA polymer 
showed similar GPC results at both 60ᵒC and 90ᵒC reaction conditions with polymerization with 
a molecular weight of 6000. The addition of DBU catalyst caused the reaction product to be fully 
crystalline and no GPC results could be gathered. PEGDA-IBA was unable to form polymer under 
any temperature or catalyst condition. This may be due to PEGDA being hydrophilic and IBA 
being hydrophobic. HEXDA and DEGDA both had mixed results concerning polymerization with 
IBA. Lower temperature at 60ᵒC produced no polymerization. HEXDA polymerized with IBA at 
90ᵒC and the GPC molecular weight was 1400. HEXDA polymerized with IBA to an even greater 
extent with the addition of DBU as the GPC molecular weight was 4000. DEGDA-IBA 
polymerization followed a similar pattern where DEGDA polymerized with IBA at 90ᵒC and the 
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GPC molecular weight was 2000. DEGDA polymerized with IBA to an even greater extent with 
the addition of DBU as the GPC molecular weight was 4000. 
Table 5-2: CPBAE molecular weight as a function of reaction conditions 
 CMA HEXDA DEGDA PEGDA 
60°C 6000 No signal No signal No signal 
90°C 6000 1400 2000 No signal 
60°C + DBU No signal No signal No signal No signal 
90°C + DBU No signal 4000 4000 No signal 
 
5.3.2.5 SEM imaging Curcumin Poly(beta-amino ester) 
SEM images were taken of the polymer film. From the SEM image it can be seen that the 
polymer is brittle as many cracks are seen after the solvent evaporation process. 
 
Figure 5-7: SEM image of Curcumin Poly(beta-amino ester) polymer 
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5.3.2.6 Solvent Cast Curcumin Poly(beta-amino ester) films 
CPBAE-PLGA polymer films were synthesized using precipitated 1:1.5 CPBAE and 50,000 
molecular weight PLGA. The weight percent PLGA in the polymer was increased from 0 to 100 in 
increments of 20.  After the films were evaporated phase separation between CPBAE and PLGA 
was observed in the 40wt% PLGA group and to a lesser extent in the 20wt% PLGA group. 0wt% 
PLGA, 20wt% PLGA and 40wt% fractured upon mechanical stimulation.  60wt% PLGA, 80wt% 
PLGA and 100wt% PLGA were more pliable and less prone to brittle fracture upon mechanical 
stimulation. 
 
 
Figure 5-8: Solvent cast PLGA:CPBAE films in DCM 
 
5.3.2.7 Differential Scanning Calorimetry Curcumin Poly(beta-amino ester) 
Differential Scanning Calorimetry was performed on solvent cast CPBAE-PLGA polymer 
films from 0wt% PLGA to 100wt% PLGA in increments of 20wt%. The glass transition 
temperature was found to be highest with 0wt% PLGA at 68ᵒC. As the percentage of PLGA in the 
polymer was increased the glass transition temperature decreased to a minimum of 33ᵒC at 
100wt% PLGA. This data correlates to observations of the macroscopic films and their brittle 
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behavior. If CPBAE were to be molded or extruded, it will be necessary that it has a lower glass 
transition point. Addition of PLGA at 40wt% or 60wt% may be necessary to achieve this end. 
 
 
Figure 5-9: Glass transition temperature as a function of CPBAE content 
 
5.3.2.8 FTIR Curcumin Poly(beta-amino ester) 
Significant points of interest are the 2800-3000 range which indicates carboxylic acid, 
the 3300-3500 range which represents amine groups and the 3500 sharp peak which represents 
a phenol group. Carboxylic acid and amine groups are present in the CPBAE. The best indicator 
for polymerization however would be C-N bonds which are characteristic at 1000-1250. This is 
obscured by other peaks and is hard to distinguish however. There was no sharp peak observed 
at 3500, which shows that the CMA did not have and phenol groups like the curcumin. 
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Figure 5-10: Curcumin Poly(beta-amino ester) FTIR spectrogram 
 
5.3.3 Curcumin Poly(beta-amino ester) Nanoparticle Synthesis 
5.3.3.1 Dynamic Light Scattering (DLS) Size Characterization 
PLGA nanoparticles, CPBAE nanoparticles and 30:70 CPBAE:PLGA nanoparticles were 
prepared using nanoprecipitation. PLGA nanoparticles were found to have a Z-average diameter 
of 70.8 +/- 1.7 nm and a PDI of 0.031 +/- 0.022. CPBAE nanoparticles had a Z-average diameter 
of 92.5 +/-19.5 nm and a PDI of 0.026 +/- 0.011. 30:70 CPBAE:PLGA blended nanoparticles had a 
Z-average diameter of 86.5 +/- 6.3 nm and a PDI of 0.015 +/- 0.013. This nanoparticle size is ideal 
for drug delivery as particles above 200 nm are not effective in intravenous delivery. The 
stability of the particles was tested for the same groups using zeta potential. The zeta potential 
was observed to be -30.2 +/- 2.3 mV, -20.3 +/- 3.6 mV and -28.1 +/- 1.8 mV for PLGA 
nanoparticles, CPBAE nanoparticles and 30:70 CPBAE:PLGA nanoparticles respectively. A 
nanoparticle suspension with zeta potential with absolute value 60 mV has excellent stability. 
An absolute value of 30 mV has moderate stability and 0 mV is prone to rapid aggregation. The 
stability of the 30:70 nanoparticles in DI water was tested further tested as the zeta potential 
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did not indicate strong stability. The particles started at a Z-average diameter of 97 nm and 
plateaued at approximately 120 nm by 10 hours. This indicates that the particles are relatively 
stable and remain under 200 nm in size. 
 
Figure 5-11: Characterization of CPBAE nanoparticle size and shape (A) DLS size 
characterization of nanoparticles (B) Zeta potential characterization of nanoparticles (C) DLS size 
characterization of 30:70 CPBAE:PLGA nanoparticles over time 
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5.3.3.2 SEM Imaging of Nanoparticles 
SEM images of 30:70 CPBAE:PLGA nanoparticles were taken to further examine the size 
distribution and morphology of the particles. SEM images show that the particles are 
approximately 120 nm which is in line with DLS data gathered. The particles take the form of 
dented spheres which is unusual. This may be due to CPBAE and PLGA being of different 
molecular weights and structures, creating imperfect spheres when mixed. 
 
 
Figure 5-12: SEM image 30:70 CPBAE:PLGA Nanoparticles 
 
5.3.4 Release of Curcumin from Curcumin Poly(beta-amino ester) 
5.3.4.1 UV Vis characterization of Curcumin Release 
CPBAE polymer was solubilized in acetone and then added into 0.1wt% SDS PBS for 
nanoparticle degradation trials. Solid CPBAE was added into 0.1wt% SDS PBS directly for the 
solid polymer degradation trial. Both experiments measured the curcumin release through UV 
Vis. Curcumin nanoparticles had a high initial burst release of curcumin where 5% of the total 
load was released by the first time point. The solid polymer exhibited no release of curcumin for 
5 days. This is most likely due to polymer swelling with water before it could hydrolytically 
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degrade. Although the initial release pattern differs, both systems have a maximum release of 
theoretical curcumin at approximately 20%. This indicates that the theoretical maximum 
curcumin is not correct. This could be due to CMA not being ideal, side reactions creating non-
ideal CPBAE polymer or a combination of both. 
 
 
Figure 5-13: Fraction total release of curcumin over time 
 
5.3.4.2 Nanoparticle Curcumin Release HPLC 
CPBAE polymer was solubilized in acetone and then added into 0.1wt% SDS PBS for 
nanoparticle degradation trials. Samples were taken at time points and centrifuged at 10,000 
rpm for 5 minutes. The supernatant collected was measured for curcumin content using HPLC. 
An initial burst release of approximately 1% theoretical maximum curcumin was released. The 
108 hour time point was observed to have 7% theoretical maximum release of curcumin. This 
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value only accounts for the curcumin release elution peak at 8 minutes however, and 
degradation products contain a curcumin and curcuminoid peak. This curcuminoid peak at 11 
minutes elution time would add to the curcumin release intensity in UV Vis, but does not 
contribute when specifically measuring curcumin release in HPLC. This indicates that a 
significant portion of the polymer does not simply degrade into curcumin. This also shows that a 
significant portion of other UV-Vis measurements of CPBAE degradation products is from 
curcuminoids as well as curcumin. 
 
Figure 5-14: Curcumin release from CPBAE over time HPLC integration 
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Figure 5-15: HPLC 420nm chromatograms of curcuminoids (A) 100µg/ml Curcumin (B) 
100µg/ml CMA (C) 108 hour CPBAE Supernatant 
 
5.3.4.3 Nanoparticle Curcumin Release GPC 
CPBAE polymer was solubilized in acetone and then added into 0.1wt% SDS PBS for 
nanoparticle degradation trials. Samples were taken at time points and centrifuged at 10,000 
rpm for 5 minutes. The precipitate was collected to measure molecular weight of the polymer 
over time. The molecular weight of the CPBAE steadily decreased over time indicating 
degradation, it only reduces by 50% of its initial molecular weight after 200 hours however. This 
is indicating that the polymer is not fully breaking down through hydrolytic degradation. 
With the similar conditions, CPBAE polymer was solubilized in acetone and then added 
into 0.1wt% SDS PBS for nanoparticle degradation trials. Samples were taken at time points and 
the entire solution was freeze dried. The solid recovered after freeze drying was dissolved in THF 
and characterized through GPC. GPC UV-Vis chromatograms at 420nm were developed for each 
time point. A polymer peak was observed from 14 to 21 minutes elution time and a low 
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molecular weight particle peak was observed after 21 minutes. As time goes on in degradation, 
the polymer peak decreases in volume while the low molecular weight particle peak increases in 
volume. This trend is captured by graphing the percentage of total volume that the 
curcuminoids in polymer take up of the total curcuminoid volume in the chromatogram at each 
time point. With no degradation, 93% of the volume of the chromatogram is taken up by 
polymerized curcuminoids. After 140 hours of degradation, 65% of the chromatogram’s volume 
is occupied by polymerized curcuminoids. This shows similarly that the CPBAE polymer is 
degrading but not fully in 140 hours. 
 
  
58 
 
 
Figure 5-16: GPC assessment of degraded CPBAE molecular weight over time (A) 
Molecular weight of degraded CPBAE (B) Polymer peak integration GPC 420nm chromatogram 
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Figure 5-17: CPBAE degradation over time GPC 420nm chromatogram (A) 0 hr (B) 24 hr 
(C) 48 hr (D) 72 hr (E) 140 hr 
 
5.4 Discussion 
The experiments carried out in the chapter were successful in developing a CPBAE 
polymer that can be formed into nanoparticles through nanoprecipitation and hydrolytically 
degrade to release curcumin. The nanoparticles were of ideal size for intravenous delivery and 
had the capability to be coated with antibodies for immunotargeting. Due to inconsistencies in 
measured release of curcumin from the polymer and the theoretical maximum release of the 
curcumin though, the structure and purity of the polymer is brought into question. The percent 
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maximum theoretical release was consistently peaking at 20%. This indicates that the polymer’s 
actual curcumin content is very far from ideal assumptions. Either curcumin is inaccessible from 
free radical polymerization or the CMA is far from pure. CMA, HPLC and GPC results were the 
first point of interest. HPLC showed that the CMA did not have any curcumin present but when 
GPC of the CMA was performed, IR spectra showed a significant amount of material in the 1000-
10000 molecular weight elution range, while 420 nm UV-Vis spectra showed that approximately 
50% of curcuminoid material was eluted in this high molecular weight peak. This could mean 
that side reaction in CMA synthesis are polymerizing the monomer. In this case, during CPBAE 
synthesis the polymerized CMA is not able to react with amines to form a linear polymer. 
Another point of friction in examining the polymer was the long degradation time of the 
polymer. This was not able to be adjusted for though reaction conditions and changing of 
reactants. Both CMA and IBA were chosen as acrylate and primary amine respectively for the 
PBAE reaction. Although this system had a high molecular weight, both were very hydrophobic 
molecules. This leads to the CPBAE degrading much slower than if it had more hydrophilic 
components. When this tuning was attempted by polymerizing CMA with hydrophilic amines, 
not reaction occurred. As CMA is a required component for the system and very hydrophobic 
this limited the options for further adjustment. 
 
5.5 Conclusions 
CMA was successfully synthesized and it was confirmed that acrylation took place and 
no curcumin remained. CPBAE was successfully polymerized using a Michael with curcumin 
multiacrylate and isobutylamine. This polymer’s chemical structure and properties were 
characterized revealing that significant polymerization was taking place, reaching an average 
molecular weight of 6000. Nanoparticles of the desired size were produced from the CPBAE and 
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these were tested for curcumin release through degradation. CPBAE nanoparticles synthesized 
were able to successfully release curcumin through degradation. The lack of tune-ability of the 
polymer composition and degradation profile was the greatest detriment.  
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Chapter 6: Conclusions and Future Directions 
Through this project, curcumin has been characterized as a radioprotectant and 
polymerized to for a degradable delivery system. The in vitro effect of curcumin pretreatment 
on radiation damage on HUVEC was first investigated. The effect of radiation both confluent and 
proliferating cells was characterized and it was found that even at high doses of radiation, 
confluent cells showed little reduction in viability, but radiation did inhibit the growth of 
proliferating HUVECs. From this, a proliferating cell model with a high dose of radiation was 
utilized for testing. Curcumin was shown to reduce the viability of irradiated cells in a dose 
dependent manner, while trolox at all concentrations tested had no effect of cell viability. 
Curcumin and trolox were shown to decrease DCF fluorescence after radiation damage 
indicating reduction in radiation damage. When the cellular response in cells was evaluated in 
the γ-H2AX foci Formation Assay, no protection in DNA breaks was found. These results show 
that antioxidant effect is not protecting cells in this model. This is emphasized by trolox not 
attenuating radiation damage to cell viability. Curcumin further reduces cell viability as it has 
been shown to have anti-proliferative effects in vitro. This indicates that curcumin’s 
radioprotective effects is not through antioxidant effect directly, rather through its anti-
inflammatory properties which are seen in vivo.  A Michael addition reaction method was used 
to produce curcumin poly(beta-amino ester). CPBAE was synthesized and characterized. Testing 
positively indicated polymerization during the reaction. Nanoparticles were synthesized using 
the developed CPBAE and were able to be size controlled for the desired application of 
intravenous delivery. Nanoparticles were found to be stable but degraded very slowly through 
hydrolysis. Both the CPBAE nanoparticles and bulk CPBAE polymer only released a maximum of 
20% of the theoretical yield.  
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Future effort could be put into analyzing the structure of CMA synthesized. The lack of 
knowledge on the CMA products structure will no doubt cause difficulty when developing future 
systems. The first step should be to perform chromatography on the CMA and separate the high 
molecular weight peak and low molecular weight peak. With these samples separated, mass 
spectrometry and FTIR could be run on each to analyze the structure. This data would dictate 
future steps in developing a separation of the final CMA product. The simplest way to purify the 
CMA would be a precipitation and it would work well for bulk material. If no method was 
feasible, then a more direct chromatography separation would be needed. The peaks are 
separated distinctly in GPC, but this method does not lend itself well large quantities of material. 
With a purified CMA, many more options would likely be available for synthesis with other 
amine and acrylate molecules. This would allow for much greater tuning of both molecular 
weight and degradation rate of polymer. This would be desirable for developing systems for 
multiple applications. 
Tuning of the radiation model may be necessary to see protective effects of curcumin. 
20 Gy of gamma radiation is a very high dose and as seen by the γ-H2AX foci formation assay, 
this radiation activates close to the maximum number of histones in the assay, thus saturating 
the test and no protective effect can be seen. At a lower radiation level such as 2 Gy or 5 Gy this 
damage would not be as great and the saturation would be removed. This would allow 
protective or damaging effects of curcumin to be measured. It has been difficult to show that 
curcumin has beneficial effects to radiation damaged cells in vitro [97] so this may still not show 
a benefit. Although an in vitro model tuned to characterize damage will be useful, it may be 
necessary to test curcumin polymer in an in vivo environment to see the full radioprotective 
effects as vascular permeability and leukocyte recruitment, both of which cannot be 
represented in a simple in vitro model. 
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